Saluda Medical, Inc. (ASX:SLD): Closed-Loop Spinal Cord Stimulation and 2026 Device Expansion

Aditi Sarkar

14 October 2026 12:25 AM AEDT

Saluda Medical, Inc. (ASX:SLD): Closed-Loop Spinal Cord Stimulation and 2026 Device Expansion

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Saluda Medical develops medical devices for chronic neurological conditions, with a focus on closed-loop neuromodulation.
The Evoke System measures neural responses and adjusts spinal cord stimulation in real time.
EVA Sensing Technology received European CE certification with recognition in Australia in January 2026.
The company announced a further US device approval and initial surgical use of CAP24 paddle leads during 2026.
Clinical adoption, reimbursement, device deployment and funding remain relevant business considerations.

Saluda Medical, Inc. (ASX:SLD) is a medical device company developing closed-loop neuromodulation treatments for chronic neurological conditions. Its Evoke spinal cord stimulation system is designed to measure neural responses during treatment and adjust stimulation accordingly. During 2026, regulatory progress for its EVA sensing technology and additional device developments expanded the company’s product-related activities across international markets.

How Evoke Measures Neural Activity

Conventional spinal cord stimulation delivers electrical pulses to influence pain-related nerve signalling. Saluda Medical (ASX:SLD) uses a feedback-based approach through its Evoke System: the device records evoked compound action potentials, or ECAPs, which are electrical responses generated by stimulation.

The system’s SmartLoop technology uses those signals to adjust stimulation on each pulse against a prescribed level. Such functionality is intended to maintain therapy delivery as spinal cord sensitivity changes, although patient response and treatment suitability remain clinical matters.

EVA Receives European Certification in 2026

On 8 January 2026, Saluda Medical (ASX:SLD) announced that EVA Sensing Technology had received CE certification for commercialisation in Europe, with that approval recognised in Australia. EVA builds on the Evoke platform by scanning and analysing a patient’s spinal cord and automating elements of programming. The company outlined a limited commercial release in Europe and Australia during the first quarter of calendar 2026, followed by a broader release later in the year.

For Saluda Medical (ASX:SLD), the announcement concerned an extension of its device platform rather than evidence of a newly completed clinical trial. Regulatory clearance permits relevant commercial activity within its scope; it does not establish identical outcomes for every patient or guarantee uptake across healthcare systems.

Additional Device and Corporate Developments

The company’s 2026 ASX announcement record also includes US regulatory approval for its CAP24 surgical paddle lead in June and an update concerning the first US surgical cases in July. These disclosures relate to the use of additional lead configurations within the company’s neuromodulation offering. They should be distinguished from commercial sales volumes, which require separate financial reporting.

Saluda Medical (ASX:SLD) released FY26 results information in August 2026 and consolidated financial statements in September.

Clinical Adoption and Operating Considerations

Commercial deployment of implantable stimulation devices involves clinician training, procedural access, hospital purchasing decisions and reimbursement arrangements. For Saluda Medical (ASX:SLD), the availability of EVA and the CAP24 lead does not by itself indicate the rate at which hospitals adopt either product. Uptake is better assessed using reported implantation activity, financial disclosures and subsequent company updates.

Device businesses also face manufacturing and supply requirements, post-market monitoring, regulatory compliance and clinical competition. Saluda Medical (ASX:SLD) must support the use of its technology in the jurisdictions where it is marketed. Any claim that a particular product development has already improved earnings would require disclosed financial evidence.

Key Insights

Saluda Medical (ASX:SLD) entered its 2026 reporting period with a differentiated approach to spinal cord stimulation based on real-time neural measurement. January’s EVA certification in Europe and Australia, followed by CAP24-related announcements, established identifiable product milestones. The broader commercial significance depends on documented device adoption, access to care, regulatory obligations and the financial results reported by the company.

FAQs

Q: What does Saluda Medical develop?

A:It develops neuromodulation medical devices, including the Evoke closed-loop spinal cord stimulation system for chronic pain treatment.

Q: What is an ECAP?

A:An evoked compound action potential is an electrical neural response measured after spinal cord stimulation.

Q: What happened to EVA in January 2026?

A:Saluda announced European CE certification for EVA Sensing Technology, with recognition of that approval in Australia.

Q: What is the CAP24 development?

A:The company announced US regulatory approval for its CAP24 surgical paddle lead and subsequently reported initial US surgical cases.

Q: Does regulatory approval confirm sales growth?

A:No. Regulatory permission and commercial sales are separate measures; sales require evidence from company financial or operating disclosures.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.